Abstract

PurposeTo examine the psychometric properties of the Injection Pen Assessment Questionnaire (IPAQ) including the following: 1) item and scale characteristics (e.g., frequencies, item distributions, and factor structure), 2) reliability, and 3) validity.MethodsFocus groups and one-on-one dyad interviews guided the development of the IPAQ. The IPAQ was subsequently tested in 136 parent–child dyads in a Phase 3, 2-month, open-label, multicenter trial for a new Genotropin® disposable pen. Factor analysis was performed to inform the development of a scoring algorithm, and reliability and validity of the IPAQ were evaluated using the data from this two months study. Psychometric analyses were conducted separately for each injection pen.ResultsConfirmatory factor analysis provides evidence supporting a second order factor solution for four subscales and a total IPAQ score. These factor analysis results support the conceptual framework developed from previous qualitative research in patient dyads using the reusable pen. However, the IPAQ subscales did not consistently meet acceptable internal consistency reliability for some group level comparisons. Cronbach’s alphas for the total IPAQ score for both pens were 0.85, exceeding acceptable levels of reliability for group comparisons.ConclusionsThe total IPAQ score is a useful measure for evaluating ease of use and preference for injection pens in clinical trials among patient dyads receiving hGH. The psychometric properties of the individual subscales, mainly the lower internal consistency reliability of some of the subscales and the predictive validity findings, do not support the use of subscale scores alone as a primary endpoint.

Highlights

  • Human growth hormone is produced and excreted by the anterior pituitary gland to help fuel growth during childhood and to maintain tissues and organs throughout life [1]

  • Patient-reported outcomes (PRO) measures developed to assess these injection devices should include feedback from both parents and children to better reflect how these devices are used in practice

  • The Confirmatory factor analysis (CFA) provide evidence supporting a second order factor solution for four subscales and a total score. These factor analysis results support the conceptual framework developed from previous qualitative research in patient dyads using the reusable pen [22]

Read more

Summary

Introduction

Human growth hormone (hGH) is produced and excreted by the anterior pituitary gland to help fuel growth during childhood and to maintain tissues and organs throughout life [1]. Recombinant hGH has been used to treat short stature or growth failure in children, including the following: 1) growth hormone deficiency, 2) born small for gestational age, 3) Prader-Willi syndrome, 4) Turner syndrome, 5) chronic renal insufficiency, and 6) idiopathic short stature. Ease of use is recognized by parents, physicians and nurses as a key feature in device acceptance [3] with potential to improve adherence. Injection devices, such as pre-filled syringes and manual injector pens, have been developed to make the process of preparing and administering hGH easier and more convenient. Patient-reported outcomes (PRO) measures developed to assess these injection devices should include feedback from both parents and children to better reflect how these devices are used in practice

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call